Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome [Phase 1]

View source ↗

Summary

Phase 1 safety, pharmacokinetic, and pharmacodynamic study of NBI-98854 (valbenazine) in children and adolescents with Tourette Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 1 | Status: COMPLETED